Jessica Allegretti, MD, MPH, medical director of the Crohn's and Colitis Center, Brigham and Women's Hospital, spoke on antibiotic use and other risk factors for the development of Clostridioides difficile infection.
Risk factors for the development of Clostridioides difficile infection (CDI) include antibiotic use, elderly age, proton pump inhibitor (PPI) use, and immunosuppression, with burden of disease ranging from mild to fulminant, said Jessica Allegretti, MD, MPH, medical director of the Crohn's and Colitis Center, Brigham and Women's Hospital.
Transcript
Can you speak on risk factors for the development of CDI in the hospital setting and the associated burden of disease for those infected?
Unfortunately, C difficile remains at epidemic levels. It is the most common cause of health care–associated infection in the United States, and there are several risk factors for a primary infection. The main risk factor still remains antibiotic use, and I often get asked, well, what's a good antibiotic or a safe antibiotic? And unfortunately, there isn't one.
All antibiotics portend some risk for CDI, although certainly some, such as clindamycin, have a higher risk than others. So, we really want to do antibiotic stewardship and avoid unnecessary antibiotic use. Other risk factors include elderly age, PPI [proton pump inhibitor] use, and immunosuppression.
So, with regards to the burden of disease, there is a real range. Disease can be asymptomatic to mild to fulminant. And so generally speaking, when we think about disease, we have categories based on our guidance. So, those with nonsevere disease are typically those with diarrheal illness, who are otherwise OK and out of the hospital. Those with severe disease are typically hospitalized patients who are having more profound diarrhea and may be exhibiting signs of dehydration, such as kidney failure. And then patients with fulminant disease can be critically ill and in the ICU [intensive care unit], and already have evidence of end-organ damage, such as very low blood pressure, and needing medication support for that blood pressure.
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
Dr Michael Farwell on FDG PET/CT Imaging to Predict Immunotherapy Response in Advanced Melanoma
April 15th 2024Michael Farwell, MD, associate professor of radiology at the Hospital of the University of Pennsylvania, provides insights into a study on the benefits of using 18F-fluorodeoxyglucose (FDG) PET/CT imaging to detect metabolic tumor changes in skin cancer.
Read More